{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:17:02Z","timestamp":1785838622603,"version":"3.56.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Giant, ulcerated triple-negative breast cancer (TNBC) presents major therapeutic challenges. We report a 39-year-old woman with a 14.3 cm ulcerated TNBC (cT4bNxM0) who developed infection after intravenous chemotherapy. To achieve rapid local control, a multidisciplinary team elected to perform transarterial chemoembolization (TACE), followed by systemic chemo-immunotherapy using nab-paclitaxel and the PD-1 inhibitor Toripalimab. This multimodal approach led to marked tumor regression and improvement of skin ulceration, enabling curative surgery with modified radical mastectomy and complex reconstruction. Pathology postoperative showed a complete response (Miller-Payne grade 5, ypT0N0M0). This single case suggests that integrating TACE with multimodal neoadjuvant treatment sequences may be feasible in selected patients with extreme presentations of locally advanced TNBC, particularly in patients with extensive tumor burden or poor tolerance to systemic therapy. The approach may enhance local control and elicit synergistic immune activation, offering a potential paradigm for managing extreme TNBC presentations. Further studies are required to clarify the safety, efficacy, and potential immunomodulatory effects of this approach.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1739817","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:53:58Z","timestamp":1771397638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Neoadjuvant TACE combined with chemo-immunotherapy for giant triple-negative breast cancer: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Jie","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Lin","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]},{"name":"Department of Interventional Vascular Surgery, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University)","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/cancers15092450","article-title":"Conservative surgery in cT4 breast cancer: single-center experience in the neoadjuvant setting","volume":"15","author":"Franco","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics."},{"key":"B3","doi-asserted-by":"publisher","first-page":"12478","DOI":"10.3390\/ijms241512478","article-title":"Advances in the management of early-stage triple-negative breast cancer","volume":"24","author":"Bhardwaj","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.addr.2015.12.002","article-title":"Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities","volume":"97","author":"Au","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/gs-21-608","article-title":"Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Gland Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03305-3","article-title":"Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern","volume":"47","author":"Tan","year":"2022","journal-title":"Abdom Radiol (NY)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1038\/s41598-024-56642-w","article-title":"Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/02841868509134394","article-title":"Combined transcatheter arterial embolization and regional chemotherapy for locally advanced carcinoma of the breast. A preliminary investigation","volume":"24","author":"Morimoto","year":"1985","journal-title":"Acta Radiol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"122540","DOI":"10.1016\/j.lfs.2024.122540","article-title":"Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure","volume":"342","author":"Li","year":"2024","journal-title":"Life Sci"},{"key":"B12","doi-asserted-by":"crossref","first-page":"572418","DOI":"10.3389\/fonc.2020.572418","article-title":"HMGB1, the next predictor of transcatheter arterial chemoembolization for liver metastasis of colorectal cancer","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571212","article-title":"Regulation of immunogenic cell death and potential applications in cancer therapy","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S452409","article-title":"The influence of drug-eluting beads transarterial chemoembolization on serum levels of soluble programmed cell death protein-1 in advanced hepatocellular carcinoma patients","volume":"11","author":"Ma","year":"2024","journal-title":"J Hepatocell Carcinoma."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S328294","article-title":"Transcatheter arterial embolization containing donafenib induces anti-angiogenesis and tumoricidal CD8+ T-cell infiltration in rabbit VX2 liver tumor","author":"Shi","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40779-024-00586-9","article-title":"Role of PD-1\/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy","volume":"11","author":"Godiyal","year":"2024","journal-title":"Mil Med Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.3390\/cancers13174455","article-title":"Ki-67 as a prognostic biomarker in invasive breast cancer","volume":"13","author":"Davey","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.3390\/ijms21176407","article-title":"Immunohistological expression of SOX-10 in triple-negative breast cancer: A descriptive analysis of 113 samples","volume":"21","author":"Kriegsmann","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00432-025-06257-z","article-title":"Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresecta ble hepatocellular carcinoma","volume":"151","author":"Hong","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpt.2025.04.004","article-title":"Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies","volume":"4","author":"Sutanto","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/tomography11070081","article-title":"TACE versus TARE in the treatment of liver-metastatic breast cancer: A systematic review","volume":"11","author":"Lalenis","year":"2025","journal-title":"Tomography."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.29454","article-title":"Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review","volume":"222","author":"Deipolyi","year":"2024","journal-title":"AJR Am J Roentgenol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1739817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:31:30Z","timestamp":1771932690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1739817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1739817"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1739817","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1739817"}}